A Look at the Innovations Introduced by the 2014 FOYA Category Winners
The 2014 Facility of the Year Awards program is shaping up to be one of the most noteworthy events of the year. A few weeks ago, we talked about what the pharmaceutical and biopharmaceutical industry can learn from the facilities recognized by FOYA. Category Winners have been announced and this year’s winning projects showcase some amazing innovations.
The category winners are:
Boehringer Ingelheim Pharma GmbH & Co. KG: Winner of the Facility of the Year Award for Equipment Innovation
F. Hoffmann-La Roche: Winner of the Facility of the Year Award for Sustainability
Grifols Therapeutics, Inc.: Winner of the Facility of the Year Award for Project Execution
Patheon Pharma Services (formerly DSM Biologics): Winner of the Facility of the Year Award for Process Innovation
Penn Pharmaceutical Services Ltd.: Winner of the Facility of the Year Award for Facility Integration
Pfizer Ireland Pharmaceuticals: Winner of the Facility of the Year Award for Operational Excellence
The FOYA Judging Panel also chose to award an Honorable Mention to WuXi AppTec Biopharmaceutical for their recently completed flexible CGMP bulk cell culture production facility. The facility, consisting of two parallel upstream cell culture bioreactor lines with flexible working volumes of 50l through 2,000l bioreactors and one downstream purification production line is the most advanced such facility built in the People’s Republic of China.
For nearly a century, production of Water for Injection (WFI) was universally accepted to be distillation-based. As emphasis on costs and environmental concerns has grown, pharmacopeias around the world have focused on the quality attributes of WFI to allow for consideration of other production...
Following an unprecedented two years in which the pharmaceutical industry has faced numerous challenges posed by the global pandemic, pharmaceutical manufacturing has had to react and respond to meet the rapidly changing requirements and timelines. This has necessitated a radical rethink in how we...
Continuous manufacturing (CM) is gaining traction in pharmaceutical manufacturing. The purpose of this post is to highlight some of the differences between small molecule Drug Substance (DS) and Drug Product (DP) continuous manufacturing (CM), which may be helpful in considering the development and...